Hasil Pencarian - N. Callander

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

    P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-12... oleh S. Usmani, A. Hoering, S. Ailawadhi, R. Sexton, B. Lipe, J. Valent, M. Rosenzweig, J. Zonder, M. Dhodapkar, N. Callander, T. Zimmerman, P. Voorhees, B. Durie, S. V. Rajkumar, P. Richardson, R. Orlowski

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up

    Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up oleh A. Medaglia, A.D. Cohen, H.C. Lee, S. Trudel, A-O. Abdallah, N. Callander, E. Libby, L. Karlin, S. Lonial, L. Womersley, J. Baron, E. Lewis, K. Nungesser, I. Gupta, J. Opalinska

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL

    P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL oleh A. Nooka, A. Cohen, H. Lee, A. Badros, A. Suvannasankha, N. Callander, A. Abdallah, S. Trudel, A. Chari, E. Libby, M. Chaudhry, M. Hultcrantz, K.M. Kortüm, P. Richardson, R. Popat, D. Sborov, S. Hakim, E. Lewis, B. Bhushan, B. Gorsh, I. Gupta, J. Opalinska, S. Lonial

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL

    B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL... oleh P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A.K. Nooka, S. Manier, N. Callander, L.J. Costa, R. Vij, N.J. Bahlis, P. Moreau, S.R. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Z. Yang, L. Favre-Kontula, F. Wu, J. Piasecki, M. Cook, S. Giralt

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: